Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials

Main Article Content

Bianca Maria Piraccini
University of Bologna, Bologna, Italy

Manabu Ohyama
Kyorin University Faculty of Medicine, Tokyo, Japan

Brittany Craiglow
Yale School of Medicine, New Haven, USA

Anthony Bewley
The Royal London Hospital, London, UK

Yuxin Ding
Eli Lilly and Company, Indianapolis, USA

Yun-Fei Chen
Eli Lilly and Company, Indianapolis, USA

Yves Dutronc
Eli Lilly and Company, Indianapolis, USA

Evangeline Pierce
Eli Lilly and Company, Indianapolis, USA

Frederick Durand
Eli Lilly and Company, Indianapolis, USA

Arash Mostaghimi
Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Keywords

Alopecia Areata, HRQoL, Phase 3, randomized, placebo-controlled trials, BRAVE-AA1, BRAVE-AA2

References

1. Pratt C, et al. Nat Rev Dis Primers. 2017;3:17011

2. Mostaghimi A, et al. Dermatol Ther (Heidelb). 2021;11:867-883.

3. Olsen EA, et al. J Am Acad Dermatol. 2004;51:440-447.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.186

Article Details

How to Cite
Piraccini, B. M. ., Ohyama, M. ., Craiglow, B. ., Bewley, A. ., Ding, Y., Chen, Y.-F., Dutronc, Y., Pierce, E. ., Durand, F. ., & Mostaghimi, A. . (2023). Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials. SKIN The Journal of Cutaneous Medicine, 7(2), s186. https://doi.org/10.25251/skin.7.supp.186
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>